Patrick Troop
Managing Director
Pharma Tycsa
View from the Top

Home Care and Safe Mixing Services for Public, Private Sectors

By Miriam Bello | Wed, 03/10/2021 - 17:11

Q: How has Pharma Tycsa expanded its compounding centers throughout the country?

A: Pharma Tycsa is present in nine states where we have been working on mixing components for oncological and nutritional treatments. Pharma Tycsa works with both the public and private sectors and we see a great deal of opportunity to explore and expand in this segment to benefit patients with safe therapies. Moreover, we are constantly seeking to add value to infusion processes to guarantee safe and accessible treatments.

Pharma Tycsa has been working on a home-care infusion center. As a result of the COVID-19 pandemic, we have seen that patients in need of these treatments have stopped visiting their hospital or clinic out of fear of contagion. Our commercial partners, such as laboratories, have also stopped following up on these kinds of treatments so we are working together to find ways to bring infusion to the patient’s home. This is common in other countries and now Mexico can explore its benefits too.

Q: How has Pharma Tycsa consolidated its traditional treatment distribution channels for the public sector?

A: There had been a quick and significant change in the healthcare sector even before COVID-19. The government has introduced many reforms to the sector, from creating INSABI to distribution alternatives. This has increased sales and requisitions from local health institutes and it has been very complex to personally attend to each client. Unlike the former centralized purchasing scheme where the provider scheduled a delivery time and methodology, now there are few centralized contracts (even though the government’s goal is a single centralized purchase), meaning that every local dependency has to find ways to purchase its supplies. This has affected the requirements they would normally ask suppliers to comply with. In turn, this has left us with an increased number of institutions to answer to, which involves high administrative, operational, commercial and logistics costs. As long as the government does not centralize its purchases, this scenario will continue and we must comply with it in the most cost-effective way.

Q: What changes did COVID-19 bring to Pharma Tycsa’s services?

A: Pharma Tycsa supplies specialized prescription medicines. We have noticed that patients have stopped their regular medicine purchases for treating their chronic conditions. This is a very serious matter as chronic diseases severely progress over time and pausing treatments can cause irreversible consequences to their health, leading to much higher costs. We have been working on ways to provide these treatments without having the patient visit a medical facility. Building a logistics response to this has a cost but we are presenting economic models to a variety of institutions that provide such treatments to encourage them to continue to do so. Working with different institutions has been challenging because they are focused on saving money and supplies. Nevertheless, in the future this will mean greater costs due to the progression of the disease.

The current government is very focused on savings, meaning that investment in the short term is not so well-received. We have worked on presenting how much the costs will increase in the future if chronic diseases progress based on our results working with a medium-size state. These results show that six out 10 people who consumed medicine for a chronic disease stopped doing so because of COVID-19.

Q: How has Pharma Tycsa joined the digital transformation of the healthcare sector?

A: We have adopted digitalization because we have to provide an appropriate follow-up for all distribution orders we supply. Moreover, the current healthcare tendency is to deliver care at the patient’s home instead of patients visiting hospitals or clinics. This has pushed the sector to integrate technology into its offering. Pharma Tycsa has seen the advantages of different technological tools and we also have a positive view of the many companies that have developed their own digitalization tools.

Q: What are the company’s near-term priorities?

A: We will continue investing in our mixing services and home-based infusion centers. We are also looking forward to defining care models so we can implement the right strategy to support different clients in bringing healthcare to the patient’s home. Our compound mixing services have driven us to dabble more in the private sector, which is short on this type of infrastructure.


Pharma Tycsa is a distribution, marketing, representation and project development company focused on pharmaceutical products. The company has strategic relationships with laboratories and wholesalers to support its services

Miriam Bello Miriam Bello Journalist and Industry Analyst